FDA Launches Enforcement Push on Pharmaceutical Advertising

The U.S. Food and Drug Administration is intensifying enforcement of pharmaceutical advertising regulations, issuing approximately 100 cease-and-desist notices and thousands of warning letters to companies. The regulatory action targets direct-to-consumer advertisements that fail to properly disclose side effects or create misleading impressions about medications. Senior administration officials indicated that some advertisements clearly violate existing regulations, making potential legal action straightforward.